Monday, June 8, 2020
“Mergers and consolidation in the pharmaceutical industry is bad news for patients, and could prove even more harmful as demand for affordable COVID treatments and vaccines is bound to increase. Drug corporations already have monopoly control to charge patients inflated prices for prescription drugs in the past few years. Corporations like AstraZeneca and Gilead have historically used their monopoly power to price-gouge patents for necessary medicines, charging sometimes tens of thousands of dollars for a single treatment.
In the middle of a global pandemic, our number one priority must be getting necessary vaccines and treatments to as many people as possible as quickly as possible — and we can’t do that if they’re not affordable because massive drug conglomerates are allowed to charge any price they want. Now more than ever, Congress must take action to ensure that the medicines being developed with taxpayer investments are affordable and accessible to everyone. It’s time to put our health ahead of boosting big Pharma profits.”
Taxpayer funding for COVID drugs:
Record of price gouging:
Lower Drug Prices Now is a national coalition of nearly 60 social, racial and economic justice organizations with members in all fifty states. We are committed to transformative, systemic and bold reforms to ensure everyone has access to affordable medicines — no matter where they live, what they look like or how much money they have. Learn more at ldpndev.wpengine.com and follow us on Twitter @peopleb4pharma.